Conditions: HIV Infection HIV-1 Infection Mycobacterium Avium Complex (MAC)
Keywords: healthy volunteers
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: yes

Brief summary:
Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and 25-O-desacetyl-rifabutin pharmacokinetics compared to the literature.

Detailed description:

Arms:
arm 1: Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin

Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily

Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily

Interventions: intervention 1: Rifabutin intervention 2: Maraviroc
Intervention descriptions: intervention 1: Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days intervention 2: Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days

Protocol document: